Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer

Abstract excerpt

// Amir Noeparast 1, * , Philippe Giron 1, * , Sylvia De Brakeleer 1 , Carolien Eggermont 1 , Ulrike De Ridder 1 , Erik Teugels 1 and Jacques De Grève 2 1 Laboratory of Molecular Oncology, Vrije Universiteit, Brussels, Belgium 2 Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Brussels, Belgium * These authors contributed equally to this work Correspondence to: Jacques De...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Computational Drug Discovery Methods
• Share to Melanoma and MAPK Pathways